# Letrozole in the Treatment of Severe and Recurrent Endometriosis

> **NCT00240942** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 40 (—)

## Conditions studied

- Severe and Recurrent Endometriosis

## Interventions

- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT00240942
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2006-06
- **Final completion:** 2006-06
- **Target enrollment:** 40 (—)
- **Last updated:** 2012-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00240942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00240942, "Letrozole in the Treatment of Severe and Recurrent Endometriosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00240942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*